Remdesivir: US buys world stock of key coronavirus drug
Trump administration goes on shopping spree leaving ‘nothing for Europe’
The US has bought the global stock of the key coronavirus drug remdesivir, leaving none for the UK, Europe or most of the rest of the world.
Remdesivir is the first drug approved by licensing authorities in the US to treat Covid-19, and one of just two drugs worldwide proven to combat the virus.
The Trump administration has bought more than 500,000 doses, which is all of the production of remdesivir for July and 90% of August and September, reports The Guardian.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar.
“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19.”
The drug is under patent to Gilead, which means no other company countries can make it - and that means the US has a monopoly on the treatment.
“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.
How does it work?
US officials say there is “clear-cut” evidence that remdesivir can cut the duration of symptoms, after clinical trials in hospitals around the world found it reduced it from 15 days down to 11.
Analysts say the drug could “have the potential to save lives, ease pressure on hospitals and allow parts of lockdown to be lifted” and the New York Times says US Food and Drug Administration already has plans to announce an emergency-use authorisation for remdesivir.
The drug is an antiviral and works by attacking an enzyme that a virus needs in order to replicate inside human cells. It was originally developed as a treatment for Ebola.
–––––––––––––––––––––––––––––––For a round-up of the most important stories from around the world - and a concise, refreshing and balanced take on the week’s news agenda - try The Week magazine. Start your trial subscription today –––––––––––––––––––––––––––––––
Dr Anthony Fauci who runs the NIAID said: “The data shows remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery.”
He claimed the results prove “a drug can block this virus” and were “opening the door to the fact that we now have the capability of treating” patients.
However, Professor Babak Javid, a consultant in infectious diseases at Cambridge University Hospitals, said remdesivir “is not a magic bullet”.
Professor Mahesh Parmar, who has run the trial in Europe, also urged caution. He said: “Before this drug can be made more widely available, a number of things need to happen: the data and results need to be reviewed by the regulators to assess whether the drug can be licensed and then they need assessment by the relevant health authorities in various countries.
“While this is happening we will obtain more and longer term data from this trial, and other ones, on whether the drug also prevents deaths from Covid-19.”
Dr Maria Van Kerkhove, the World Health Organisation’s technical lead for the coronavirus response, told CNN: “Typically, you don't have one study that will come out that will be a game changer.”
A report in the Lancet says a trial of the same drug in China found it was ineffective. However, the China trial was incomplete because the success of lockdown in Wuhan meant doctors ran out of patients.
The BBC says there are several unanswered questions over the drug: “Is it allowing people who would have recovered anyway to do so more quickly? Or is it preventing people from needing treatment in intensive care?Did the drug work better in younger or older people? Or those with or without other diseases? Do patients have to be treated early when the virus is thought to peak in the body?”
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
-
The best TV spy thrillers
The Week Recommends Brilliant espionage series, packed with plot twists to keep you hooked until the end
By Irenie Forshaw, The Week UK Published
-
Ukraine-Russia: are both sides readying for nuclear war?
Today's Big Question Putin changes doctrine to lower threshold for atomic weapons after Ukraine strikes with Western missiles
By Harriet Marsden, The Week UK Published
-
Hugh Corcoran and The Yellow Bittern: is the customer really always right?
Talking Point A new London restaurant has caused controversy by complaining about customer eating habits
By Richard Windsor, The Week UK Published
-
Last hopes for justice for UK's nuclear test veterans
Under the Radar Thousands of ex-service personnel say their lives have been blighted by aggressive cancers and genetic mutations
By Sorcha Bradley, The Week UK Published
-
'It may not be surprising that creative work is used without permission'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published
-
What message is Trump sending with his Cabinet picks?
TODAY'S BIG QUESTION By nominating high-profile loyalists like Matt Gaetz and RFK Jr., is Trump serious about creating a functioning Cabinet, or does he have a different plan in mind?
By Rafi Schwartz, The Week US Published
-
Gaetz ethics report in limbo as sex allegations emerge
Speed Read A lawyer representing two women alleges that Matt Gaetz paid them for sex, and one witnessed him having sex with minor
By Peter Weber, The Week US Published
-
The clown car cabinet
Opinion Even 'Little Marco' towers above his fellow nominees
By Mark Gimein Published
-
What Mike Huckabee means for US-Israel relations
In the Spotlight Some observers are worried that the conservative evangelical minister could be a destabilizing influence on an already volatile region
By Rafi Schwartz, The Week US Published
-
The Pentagon faces an uncertain future with Trump
Talking Point The president-elect has nominated conservative commentator Pete Hegseth to lead the Defense Department
By Justin Klawans, The Week US Published
-
'All Tyson-Paul promised was spectacle and, in the end, that's all we got'
Instant Opinion Opinion, comment and editorials of the day
By Justin Klawans, The Week US Published